Gene delivery player to go public this week, aiming to raise $100M

Regenxbio's gene therapy drug delivery tech is licensed to 8 partners, including Baxalta. It is being used by 18 candidates. The Rockville, MD, company hopes to raise $100 million in its upcoming debut on the Nasdaq. In addition, Dimension Therapeutics filed with the SEC for an IPO to raise up to $115 million on the Nasdaq. It is developing gene therapies aimed at the liver for rare genetic disorders. The fate of the two companies is tied together, as Dimension licensed its adeno-associated virus (AAV) gene delivery vector from Regenexbio. More about Rengenxbio | More about Dimension

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.